Pituitary & hypothalamus

Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls

Eur J EndocrinolPublished Cross-sectional study

Authors' conclusion

This study reveals heightened anxiety, alexithymia, depression, and diminished overall mental health in patients with AVP-D and PP. The results emphasize the need for careful interpretation of psychopathological characteristics to differentiate between AVP-D and PP.

Study context

Population
Patients with arginine vasopressin deficiency (AVP-D) or primary polydipsia (PP) and healthy controls
Participants
82 patients2 studies
Exposure
AVP-D vs PP vs healthy controls
  • AVP-Dn = 39
  • PPn = 28
  • Healthy controls (HC)n = 15reference
Outcome
Anxiety (State-Trait Anxiety Inventory (STAI)), points
Methodological detailsdata from two studies
  • Data from two studies

Main finding

As reported in the abstract

AVP-D vs HC: P < 0.01 · AVP-D vs PP: P = 0.58

Observational data: associations, not effects.

Further findings

Alexithymia (TAS-20), points — AVP-D vs HC · higher alexithymia in AVP-D and PP vs HC

P < 0.01

OutcomeAVP-DPPHCP value
Alexithymia (TAS-20), pointsAVP-D vs PP · no differenceP = 0.90
Depression (BDI-II), pointsAVP-D vs HC · higher depression in AVP-D and PP vs HC7 (range 4–14) points7 (range 3–13) points1 (range 0–2) pointP < 0.01
Depression (BDI-II), pointsAVP-D vs PP · no differenceP = 0.50
Overall mental health (SF-36)AVP-D vs HC · reduced in AVP-D60 (range 52–80)60 (range 47–74)84 (range 68–88)P = 0.05
Overall mental health (SF-36)PP vs HC · reduced in PPP < 0.01

Original publication

Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls. Eur J Endocrinol. Published 29 March 2024. doi:10.1093/ejendo/lvae040

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.